TY - JOUR
T1 - Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011
T2 - Increasing rates of HCV diagnosis but not of HCV seroconversions
AU - CoRIS
AU - Sobrino-Vegas, Paz
AU - Monge Corella, Susana
AU - Serrano-Villar, Sergio
AU - Gutiérrez, Félix
AU - Masiá, Mar
AU - López Rodríguez, Cristina
AU - Padilla, Sergio
AU - Navarro, Andrés
AU - Montolio, Fernando
AU - Robledano García, Catalina
AU - Colomé, Joan Gregori
AU - Blanco, José Ramón
AU - Santos, Ignacio
AU - Del Romero, Jorge
AU - Segura, Ferrán
AU - Portilla, Joaquín
AU - Guillén, Santiago Moreno
AU - Del Amo, Julia
AU - García, Federico
AU - Ángeles Muñoz, María
AU - Hernando Sebastián, Victoria
AU - Alejos Ferreras, Belén
AU - Álvarez, Débora
AU - Monge, Susana
AU - Jarrín, Inmaculada
AU - Rivero, Yaiza
AU - González Blázquez, Cristina
AU - Muñoz-Fernández, M. Ángeles
AU - García-Merino, Isabel
AU - Gómez Rico, Coral
AU - Gallego De La Fuente, Jorge
AU - García Torre, Almudena
AU - Portilla Sogorb, Joaquín
AU - Merino De Lucas, Esperanza
AU - Bañuls, Sergio Reus
AU - Martínez, Vicente Boix
AU - Oncina, Livia Giner
AU - Pastor, Carmen Gadea
AU - Portilla Tamarit, Irene
AU - Toledo, Patricia Arcaina
AU - Gómez Sirvent, Juan Luis
AU - Rodríguez Fortúnez, Patricia
AU - Alemán Valls, María Remedios
AU - Del Mar Alonso Socas, María
AU - López Lirola, Ana María
AU - Hernández Hernández, María Inmaculada
AU - Díaz-Flores, Felicitas
AU - Soriano, Vicente
AU - Labarga, Pablo
AU - Ibáñez, Laura
N1 - Publisher Copyright:
© 2014 Sobrino-Vegas et al.
PY - 2014/12/30
Y1 - 2014/12/30
N2 - Objectives: We aim to describe rates and risk factors of Hepatitis C Virus (HCV) diagnoses, follow-up HCV testing and HCV seroconversion from 2004-2011 in a cohort of HIV-positive persons in Spain. Methods: CoRIS is a multicentre, open and prospective cohort recruiting adult HIVpositive patients naïve to antiretroviral therapy. We analysed patients with at least one negative and one follow-up HCV serology. Incidence Rates (IR) were calculated and multivariate Poisson regression was used to estimate adjusted Rates Ratios (aIRR). Results: Of 2112 subjects, 53 HCV diagnoses were observed, IR50.93/100py (95%CI: 0.7-1.2). IR increased from 0.88 in 2004-05 to 1.36 in 2010-11 (aIRR51.55; 95%CI: 0.37-6.55). In men who have sex with men (MSM) from 0.76 to 1.10 (aIRR51.45; 95%CI: 0.31-6.82); in heterosexual (HTX) subjects from 1.19 to 1.28 (aIRR51.08; 95%CI: 0.11-10.24). HCV seroconversion rates decreased from 1.77 to 0.65 (aIRR50.37; 95%CI: 0.12-1.11); in MSM from 1.06 to 0.49 (aIRR50.46; 95%CI: 0.09-2.31); in HTX from 2.55 to 0.59 (aIRR50.23; 95%CI: 0.06-0.98). HCV infection risk was higher for injecting drug users (IDU) compared to HTX (aIRR59.63;95%CI: 2.9-32.2); among MSM, for subjects aged 40-50 compared to 30 or less (IRR53.21; 95%CI: 1.7-6.2); and among HTX, for female sex (aIRR52.35; 95%CI: 1.03-5.34) and ,200 CD4-count (aIRR52.39; 95%CI: 0.83-6.89). Conclusion: We report increases in HCV diagnoses rates which seem secondary to intensification of HCV follow-up testing but not to rises in HCV infection rates. HCV IR is higher in IDU. In MSM, HCV IR increases with age. Among HTX, HCV IR is higher in women and in subjects with impaired immunological situation.
AB - Objectives: We aim to describe rates and risk factors of Hepatitis C Virus (HCV) diagnoses, follow-up HCV testing and HCV seroconversion from 2004-2011 in a cohort of HIV-positive persons in Spain. Methods: CoRIS is a multicentre, open and prospective cohort recruiting adult HIVpositive patients naïve to antiretroviral therapy. We analysed patients with at least one negative and one follow-up HCV serology. Incidence Rates (IR) were calculated and multivariate Poisson regression was used to estimate adjusted Rates Ratios (aIRR). Results: Of 2112 subjects, 53 HCV diagnoses were observed, IR50.93/100py (95%CI: 0.7-1.2). IR increased from 0.88 in 2004-05 to 1.36 in 2010-11 (aIRR51.55; 95%CI: 0.37-6.55). In men who have sex with men (MSM) from 0.76 to 1.10 (aIRR51.45; 95%CI: 0.31-6.82); in heterosexual (HTX) subjects from 1.19 to 1.28 (aIRR51.08; 95%CI: 0.11-10.24). HCV seroconversion rates decreased from 1.77 to 0.65 (aIRR50.37; 95%CI: 0.12-1.11); in MSM from 1.06 to 0.49 (aIRR50.46; 95%CI: 0.09-2.31); in HTX from 2.55 to 0.59 (aIRR50.23; 95%CI: 0.06-0.98). HCV infection risk was higher for injecting drug users (IDU) compared to HTX (aIRR59.63;95%CI: 2.9-32.2); among MSM, for subjects aged 40-50 compared to 30 or less (IRR53.21; 95%CI: 1.7-6.2); and among HTX, for female sex (aIRR52.35; 95%CI: 1.03-5.34) and ,200 CD4-count (aIRR52.39; 95%CI: 0.83-6.89). Conclusion: We report increases in HCV diagnoses rates which seem secondary to intensification of HCV follow-up testing but not to rises in HCV infection rates. HCV IR is higher in IDU. In MSM, HCV IR increases with age. Among HTX, HCV IR is higher in women and in subjects with impaired immunological situation.
UR - https://www.scopus.com/pages/publications/84920170514
U2 - 10.1371/journal.pone.0116226
DO - 10.1371/journal.pone.0116226
M3 - Article
C2 - 25549224
AN - SCOPUS:84920170514
SN - 1932-6203
VL - 9
JO - PloS one
JF - PloS one
IS - 12
M1 - e116226
ER -